Jeffrey D. Marrazzo

CIK: 0001631262

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)6 (66.7%)

Compensation grants

Other (G, F, J, C, D, …)3 (33.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

PRME

Prime Medicine, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (9 total)

PRME
Prime Medicine, Inc.
Jun 5, 2026
Award(A)
Stock Option (right to buy)
Direct
75K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Award(A)
Stock Option (right to buy)
Direct
92K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Disposition(D)
Stock Option (right to buy)
Direct
250K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Award(A)
Stock Option (right to buy)
Direct
250K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Disposition(D)
Stock Option (right to buy)
Direct
92K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Award(A)
Stock Option (right to buy)
Direct
45K shares-
PRME
Prime Medicine, Inc.
Aug 1, 2025
Disposition(D)
Stock Option (right to buy)
Direct
45K shares-
PRME
Prime Medicine, Inc.
Jun 4, 2025
Award(A)
Stock Option (right to buy)
Direct
55K shares-
PRME
Prime Medicine, Inc.
May 19, 2025
Award(A)
Stock Option (right to buy)
Direct
800K shares-

		Type	Shares	Price		Ownership
Jun 5, 2026	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	75,000	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	92,000	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Disposition(D) Stock Option (right to buy)	250,000	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	250,000	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Disposition(D) Stock Option (right to buy)	92,000	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	45,000	-	-	Direct
Aug 1, 2025	PRME Prime Medicine, Inc.	Disposition(D) Stock Option (right to buy)	45,000	-	-	Direct
Jun 4, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	55,000	-	-	Direct
May 19, 2025	PRME Prime Medicine, Inc.	Award(A) Stock Option (right to buy)	800,000	-	-	Direct

1-9 of 9 transactions

About Marrazzo Jeffrey D

Marrazzo Jeffrey D (SEC CIK 0001631262) files insider reports with the SEC as Director of Prime Medicine, Inc. (PRME).

Signal8 holds 4 ownership filings by Marrazzo Jeffrey D, all Form 4s, filed between May 19, 2025 and Jun 8, 2026. Those filings report 9 transactions, from May 19, 2025 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Marrazzo Jeffrey D's filings is in CAMBRIDGE, MA.

Recent filings by Marrazzo Jeffrey D

Jun 5, 2026: Grant or award of PRME derivative securities (Form 4, code A).
Aug 1, 2025: Grant or award of PRME derivative securities (Form 4, code A).
Aug 1, 2025: Disposition to issuer transaction of PRME derivative securities (Form 4, code D).
Aug 1, 2025: Grant or award of PRME derivative securities (Form 4, code A).
Aug 1, 2025: Disposition to issuer transaction of PRME derivative securities (Form 4, code D).

Other insiders filing for Prime Medicine, Inc. (PRME)

Schenkein David P, Director
NELSEN ROBERT, Director
Kelly Michael Aaron, Director
Foster-Cheek Kaye I, Director
Chung Wendy, Director
Cahill Thomas, Director

How to read Form 4 transaction codes